Microbix Biosystems Inc. has seen a slight decline in its stock price this week, reflecting broader trends in the healthcare sector.
Microbix Biosystems Inc. (MBX.TO) has had a tough week, with its stock price dropping by 4.84%. It closed at C$0.29, down 1.67% for the day. Despite some positive news about the company’s financial performance, overall market conditions and investor sentiment seem to be affecting the stock.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$40.41M
52W high
$0.33
52W low
$0.21
1W change
-4.84%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX · as of Sep 17, 2026
Wall Street analysts forecast MBX stock price to fall 99.3% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
-99.3% Upside
Current Price
C$55.39
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
54.8%
Annualized
90-Day Vol
49.0%
Annualized
Trend (90d)
-7.1%
Annualized drift
90d Mean
C$0.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.29 | C$0.24 – C$0.35 |
| 60 trading days | C$0.29 | C$0.22 – C$0.38 |
| 90 trading days | C$0.29 | C$0.21 – C$0.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Microbix's upcoming earnings and market conditions, as these could impact future performance. The recent revenue growth is encouraging, but there are still challenges ahead.
Microbix Reports 17% Revenue Increase Amid Ongoing Losses
In Q3 Fiscal 2026, Microbix reported a significant revenue increase of 17%. However, the company is still facing financial difficulties, with a profit margin of -31.7% and an EPS of -0.04.
Bull case
The 17% year-over-year revenue growth in the latest quarterly report suggests that Microbix has the potential for future profitability. The company is working to optimize its operations and expand its market presence, which could lead to better results down the line.
Bear case
On the flip side, Microbix's negative profit margin and ongoing net losses highlight financial challenges that could affect its stock performance in the near term.
Price Action Overview
Advertisement
Microbix Biosystems Inc. (MBX.TO) finished the last trading session at C$0.29, marking a 1.67% decrease for the day. Over the past week, the stock has dropped by 4.84%, likely due to broader market trends impacting the healthcare sector.
Recent Company News
This week, there were no specific announcements from Microbix. However, the company recently shared its Q3 Fiscal 2026 results, showing a 17% increase in revenues compared to last year. Despite this positive news, the company is still dealing with a net loss, which may have contributed to the stock's decline.
Technical Picture
Currently, Microbix is trading slightly below its 50-day moving average of C$0.30, indicating a potential short-term bearish trend. The stock's 200-day moving average is at C$0.26, suggesting a longer-term bullish trend. The 52-week range for MBX.TO has been between C$0.21 and C$0.33, with the current price at 71% of this range. The stock has a beta of 0.57, indicating lower volatility compared to the broader market. Trading volume has also been low, with the latest volume at 2,050 shares, significantly below the 20-day average of 23,691 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
